ShardaCare-Healthcity Launches Institute of Bone Marrow Transplant in Greater Noida

The facility will address conditions including leukaemia, lymphoma, multiple myeloma, aplastic anaemia, bone marrow failure syndromes, thalassemia, and sickle cell disease, including high-risk and complex transplant cases.

ShardaCare-Healthcity has announced the launch of its Institute of Bone Marrow Transplant (BMT) aimed at treating complex blood disorders in both paediatric and adult patients.

The facility will address conditions including leukaemia, lymphoma, multiple myeloma, aplastic anaemia, bone marrow failure syndromes, thalassemia, and sickle cell disease, including high-risk and complex transplant cases.

According to the hospital, the institute has been designed to offer a comprehensive range of bone marrow transplant procedures. These include matched sibling donor transplants, matched unrelated donor transplants, haploidentical (half-match) transplants, and autologous transplants. The facility will also support transplants for selected autoimmune conditions such as multiple sclerosis.

The institute has been strengthened with the appointment of Dr Pawan Kumar Singh, haemato-oncologist and bone marrow transplant specialist, as Vice Chairman, Department of Haemato-Oncology and BMT. Dr Singh will lead the clinical and operational development of the institute, supported by Dr Isha, Associate Consultant, the hospital said.

In addition to transplant services, the institute will provide access to advanced treatment modalities, including high-dose induction therapy, targeted therapies, immunotherapies, graft manipulation techniques, T-cell-depleted haploidentical transplants, and CAR-T cell therapy. These therapies are increasingly being used in the management of relapsed, refractory, and high-risk blood cancers and disorders.

India continues to see a rising burden of inherited and acquired blood disorders among both children and adults. Limited awareness, delayed diagnosis, donor availability challenges, and high treatment costs remain key barriers to timely care, the hospital noted. Advances in bone marrow transplantation and emerging gene and cellular therapies, however, are contributing to improved survival rates and quality of life for patients.

Commenting on the launch, Dr Singh said access to bone marrow transplantation in India remains restricted due to factors such as delayed referrals and donor shortages. “Outcomes are significantly better when transplantation is undertaken early, especially in adults. Through this institute, we aim to strengthen early diagnosis, donor matching, and access to advanced therapies,” he said.

Dr Kousar Shah, Group CEO, ShardaCare-Healthcity, said the institute aims to build a sustainable transplant ecosystem capable of serving patients across age groups. He added that the focus would be on combining clinical expertise with initiatives to improve access to specialised care for patients requiring bone marrow transplantation.

Stay tuned for more such updates on Digital Health News